UBS Asset Management Americas Inc. cut its position in shares of Inogen, Inc (NASDAQ:INGN) by 40.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,200 shares of the medical technology company’s stock after selling 2,200 shares during the period. UBS Asset Management Americas Inc.’s holdings in Inogen were worth $215,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Norges Bank acquired a new position in shares of Inogen during the fourth quarter worth $18,813,000. Congress Asset Management Co. MA purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $539,000. Guggenheim Capital LLC purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $211,000. Tudor Investment Corp Et Al purchased a new stake in shares of Inogen during the fourth quarter valued at approximately $289,000. Finally, Menta Capital LLC boosted its stake in shares of Inogen by 115.2% in the fourth quarter. Menta Capital LLC now owns 15,504 shares of the medical technology company’s stock valued at $1,041,000 after buying an additional 8,300 shares during the last quarter.
Shares of Inogen, Inc (INGN) traded up 1.58% on Monday, hitting $93.77. The stock had a trading volume of 211,492 shares. The stock’s 50-day moving average price is $86.78 and its 200 day moving average price is $74.20. The company has a market cap of $1.93 billion, a PE ratio of 83.87 and a beta of 1.04. Inogen, Inc has a 52 week low of $44.26 and a 52 week high of $95.43.
Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, May 9th. The medical technology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.15. Inogen had a return on equity of 11.67% and a net margin of 9.32%. The company had revenue of $52.50 million during the quarter, compared to analysts’ expectations of $49.06 million. During the same quarter in the previous year, the firm earned $0.12 EPS. Inogen’s revenue was up 22.1% on a year-over-year basis. On average, analysts predict that Inogen, Inc will post $1.04 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/inogen-inc-ingn-position-decreased-by-ubs-asset-management-americas-inc-updated-updated/862473.html.
INGN has been the subject of several recent research reports. Needham & Company LLC boosted their price target on Inogen from $78.00 to $83.00 and gave the company a “strong-buy” rating in a research note on Wednesday, March 1st. Stifel Nicolaus upped their target price on Inogen to $65.00 in a research report on Wednesday, March 1st. J P Morgan Chase & Co set a $78.00 target price on Inogen and gave the stock a “buy” rating in a research report on Wednesday, March 1st. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a research report on Thursday, March 2nd. Finally, TheStreet raised Inogen from a “c” rating to a “b-” rating in a research report on Tuesday, February 28th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $86.80.
In other news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $91.54, for a total transaction of $228,850.00. Following the completion of the transaction, the executive vice president now owns 4,833 shares of the company’s stock, valued at approximately $442,412.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Raymond Huggenberger sold 15,300 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $90.88, for a total value of $1,390,464.00. Following the transaction, the director now directly owns 7,808 shares of the company’s stock, valued at approximately $709,591.04. The disclosure for this sale can be found here. Insiders have sold a total of 83,848 shares of company stock valued at $7,283,201 in the last three months. 5.31% of the stock is owned by insiders.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with our FREE daily email newsletter.